News

A dive into the intricacies of how to ensure a long-running event stays fresh and relevant to the needs of the pharmaceutical industry.

Investigators examine the validity of phosphodiesterase type 5 inhibitors for erectile dysfunction, such as Viagra, being repurposed for the treatment of Alzheimer's disease.

JNJ-2113, a novel, oral IL-23–receptor antagonist peptide showed significant efficacy in patients with moderate-to-severe plaque psoriasis compared with placebo.

A study investigates the effectiveness of bivalent mRNA COVID-19 vaccines against the Omicron variant among participants 5-17 years of age.

The FDA placed a full clinical hold on magrolimab for hematologic cancers after data showed the drug in combination with azacitidine plus Venclexta increased the risk of death related to infections and respiratory failure in patients with acute myeloid leukemia.

Data suggest that dosing of MariTide may be effectively tapered down and the drug may be taken less frequently over time compared with GLP-1 agonists such as Wegovy and Zepbound.

Trial for the treatment of ATTR-CM demonstrated an 81% absolute survival rate, along with an observed mean annual CVH frequency of 0.29.

The pharma powerhouse is investing $300 million in a plant that could be vital for the future cancer trials.

Phase III CheckMate -77T trial data show statistically significant improvements in event-free survival with Opdivo (nivolumab) plus chemotherapy followed by surgery and adjuvant Opdivo in the treatment of resectable stage IIA to IIIB non-small cell lung cancer.

Cohort study dives into whether low income subsidy losses are associated with disability status, age, and race and ethnicity.

BioNTech SE and Duality Biologics Co's BNT325/DB-1305 is a next-generation antibody-drug conjugate that targets the TROP2 protein, which is overexpressed across various tumor types.

Arexvy was the first FDA-approved respiratory syncytial virus (RSV) vaccine to prevent lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

The air cargo market numbers close out the year slightly below 2022’s performance.

The February issue is centered around third-party logistics providers, including new dynamics and future trends that affect this key supply chain link.

A cohort study investigates the impact of Senate Bill 2994A and answers the question: does the repeal of school-entry nonmedical vaccination exemptions result in a rise in school vaccinations?

UV1 is an off-the-shelf vaccine that has demonstrated a survival benefit in combination with ipilimumab (Yervoy) and nivolumab (Opdivo) in patients with unresectable malignant pleural mesothelioma.

The acquisition expands Merck’s portfolio in the veterinary pharma space.

The deal is expected to help boost supply of Wegovy.

Pharma Commerce travels to Orlando for a pulse-check on this fast-evolving landscape in patient care.

And the need to boost awareness of this critical healthcare resource.

An analysis of the two main new models for pharmacy—unique direct—to-consumer for brands and cash pay for generics—and what members of industry think about them.

An analysis conducted by RAND Corporation determines that majority of new Rx medications are first sold in the United States before making their debut in other countries.

New reservation program for Beyfortus (nirsevimab-alip) seeks to improve access to the monoclonal antibody that is FDA-approved to protect against respiratory syncytial virus-associated lower respiratory tract disease.

A dive into this market reveals that the latest numbers yield promising results—a global value of a worldwide $1.6 trillion—but it will continue to be attributed to past, present, and future healthcare spending.

Allarity reached an agreement with Novartis in 2018 to license dovitinib, a small molecule multi-tyrosine kinase inhibitor under evaluation for the treatment of renal cell carcinoma.

Treatment with the novel engineered T-cell receptor produced an overall response rate of about 39% in patients with heavily pretreated synovial sarcoma.

Leading experts in the sector explore the value of third-party logistics providers when it comes to fortifying pharmaceutical supply chains.

BST02 is a novel cell-based immunotherapy currently being evaluated in a Phase I trial for the treatment of all types of liver cancer.